KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Receivables: 2013-2024

Historic Receivables for Xenon Pharmaceuticals (XENE) over the last 11 years, with Dec 2024 value amounting to $2.9 million.

  • Xenon Pharmaceuticals' Receivables rose 938.30% to $8.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $13.4 million, marking a year-over-year increase of 188.63%. This contributed to the annual value of $2.9 million for FY2024, which is 236.16% up from last year.
  • Xenon Pharmaceuticals' Receivables amounted to $2.9 million in FY2024, which was up 236.16% from $874,000 recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Receivables peaked at $2.9 million during FY2024, and registered a low of $874,000 during FY2023.
  • Its 3-year average for Receivables is $1.6 million, with a median of $986,000 in 2022.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Receivables slumped by 64.34% in 2022 and then soared by 236.16% in 2024.
  • Xenon Pharmaceuticals' Receivables (Yearly) stood at $1.8 million in 2020, then soared by 51.76% to $2.8 million in 2021, then plummeted by 64.34% to $986,000 in 2022, then dropped by 11.36% to $874,000 in 2023, then skyrocketed by 236.16% to $2.9 million in 2024.